Based on 460 companies in this sector, out of the full universe. This is a valuation (cheap/quality) view, not a momentum view — see the industry momentum pages for that angle.
This sector's average P/E is 97.7x, higher than the overall market average (58.0x) — less favorable valuation. Average ROE is -50833.9%, lower than the market average (-9233.2%), and the average debt ratio is 29117%, higher than the market average (5324%).
Akari Therapeutics Plc (P/E -38124.0), Quoin Pharmaceuticals, Ltd. (P/E -1699.3), Eton Pharmaceuticals, Inc. (P/E -1527.1), Nakamoto Inc. (P/E -1127.5), FENNEC PHARMACEUTICALS INC. (P/E -815.8)
Akari Therapeutics Plc (ROE 8642.4%), Inhibrx Biosciences, Inc. (ROE 3879.2%), Nakamoto Inc. (ROE 3336.9%), Kyverna Therapeutics, Inc. (ROE 970.2%), ESTABLISHMENT LABS HOLDINGS INC. (ROE 959.1%)
| Company | Score | P/E | P/B | ROE% |
|---|---|---|---|---|
| Entrada Therapeutics, Inc. TRDA | 88.5 | 2.7 | 0.73 | 27.1 |
| SIGA TECHNOLOGIES INC SIGA | 88.3 | 3.2 | 1.28 | 40.0 |
| USANA HEALTH SCIENCES INC USNA | 83.8 | 4.1 | 0.61 | 14.7 |
| ORASURE TECHNOLOGIES INC OSUR | 81.9 | 5.1 | 0.74 | 14.7 |
| BAXTER INTERNATIONAL INC BAX | 74.7 | 4.5 | 1.71 | 38.1 |
| SBC Medical Group Holdings Inc SBC | 74.7 | 11.6 | 2.78 | 23.9 |
| Solventum Corp SOLV | 74.4 | 10.5 | 1.20 | 11.5 |
| Amphastar Pharmaceuticals, Inc. AMPH | 74.4 | 8.9 | 2.31 | 26.0 |
| Prestige Consumer Healthcare Inc. PBH | 74.2 | 11.1 | 1.61 | 14.5 |
| Innoviva, Inc. INVA | 74.2 | 8.7 | 2.27 | 26.0 |
Not investment advice. New to P/E, P/B, or ROE? See the glossary. ← All sector reports